News

€6m to fight a fatal disease
Enlarge image

BusinessSwitzerlandEU

€6m to fight a fatal disease

16.10.2012 - The European Commission gives €6m to a research consortium tackling a severe immune system disorder. „FIGHT HLH“ is led by Swiss Novimmune.

The European Commission wants to dismantle a malicious disease. By spending €6m of FP7 money for research into hemophagocytic lymphohistiocytosis (HLH), it wants to advance knowledge about possible treatment options about this orphan disease. The awardee is a consortium of institutions named FIGHT HLH. Among the institutions are Hospitals in Florence and Rome and Lonza Biologics plc. The consortium leader, however, is based in Switzerland. Novimmune SA from Geneva is the originator of the treatment option in question: NI-0501. This fully human monoclonal antibody is a potent inhibitor of the cytokine IFNγ, Cristina de Min, the company’s Chief Medical Officer, stresses the aim of the collaboration: „The programme is designed to give a clear readout on the ability of the drug to affect disease course.“ Novimmune CEO Jack Barbut adds that he is „delighted to have been selected by the European Commission for such a prestigious grant.“

HLH is caused by an impairment of cytotoxic T cell function that triggers an anomalous activation of the immune system. This activation stems mainly from an dramatic increase in IFNγ levels. NI-0501 targets IFNγ. Novimmune tested the drug in Phase I clinical trials successfully for safety and also demonstrated in animal studies that clearing excess IFNγ with the antibody reverses organ pathology and re-establishes key clinical parameters.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/eur6m-to-fight-a-fatal-disease.html

2014EU

19.12.2014 We took a look back at 2014: which European Biotechnology News stories topped the charts this year?

R&DEUBelgium

18.12.2014 IMI has launched a €115m call for proposals involving a project in collaboration with the Bill and Melinda Gates Foundation to improve vaccines against whopping cough in children.

PoliticsEUPolandItalySpainUK

16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.

M&ALuxembourg

11.12.2014 Luxembourg bio-analytical testing company Eurofins Scientific has signed an agreement to acquire Boston Heart Diagnostics Corp. for an initial €112m.

StudySwitzerlandEU

10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.

FinancingUKSpain

09.12.2014 British drug delivery specialist Midatech Pharma plc floated on the London stock market. It is the third biotech IPO on the AIM market this year.

CooperationAustria

05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.

FinancingDenmark

03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.

Events

All Events

Current issue

All issues

Product of the week

Products